Statin use is associated with improved overall survival in patients with melanoma

Madison, Cecelia J.; Heinrich, Michael C.; Thompson, Reid F.; Yu, Wesley Y.

doi:10.1097/cmr.0000000000000822

Cited by 7 publications

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In particular, receiving targeted therapy was the strongest predictor, which could remarkably improve the survival probability of brain metastasis patients by nearly 24%. Compelling evidence has demonstrated that being overweight is a pivotal risk factor for the occurrence of common cancers [30,31]. Interestingly, higher BMI and TG levels showed a significant correlation with the survival of brain metastatic patients in the current study.…”

Section: Discussionsupporting

confidence: 51%

Association between Statin Use and Survival in Cancer Patients with Brain Metastasis: Retrospective Analysis from the Chinese Population

Liu

Wei

et al. 2022

Pharmaceuticals

View full text Add to dashboard Cite

Brain metastasis predicts a worse clinical outcome in cancer patients. Emerging observational evidence suggests that statin use has a protective role in overall cancer prevention. Whether statin use could also be a supplementary treatment for advanced-stage cancers remains under researched and controversial. Data for cancer patients with brain metastasis were selected from the linked electronic medical care records of the West China Hospital between October 2010 and July 2019. Fisher’s exact chi-square test was used to compare the differences between cohorts. Multivariate Cox analysis was conducted to adjust the potential confounders in evaluating the role of statin use in the overall survival (OS) of cancer patients with brain metastasis. There were 4510 brain metastatic patients included in this retrospective study. The overall statin use rate in our patients was 5.28% (219 cases/4510 cases). Compared with the non-statin use cohort, patients who received statin therapy showed a decreased Karnofsky performance score (KPS, p < 0.001) and lower high-density lipoprotein (HDL, p = 0.020) but higher body mass index (BMI, p = 0.002) and triglyceride (TG, p < 0.001) at admission. There was no association between statin use and the OS of the cancer patients with brain metastasis (Hazard ratio (HR) = 0.90, 95% confidence interval (CI): 0.73–1.07, p = 0.213) during the univariate analysis. However, after adjusting for baseline patient characteristics, metabolism indicators, and cancer-specific factors, statin use was shown to have a significant protective role, aiding the survival of the cancer patients with brain metastasis (adjustHR = 0.82, 95%CI: 0.69–0.99, p = 0.034). Our results highlight that statin use shows significant survival benefits in cancer patients with brain metastasis. However, future research is needed to validate our findings.

show abstract

Section: Discussionsupporting

confidence: 51%

Association between Statin Use and Survival in Cancer Patients with Brain Metastasis: Retrospective Analysis from the Chinese Population

Liu

Wei

et al. 2022

Pharmaceuticals

View full text Add to dashboard Cite

show abstract

“…[ 16 ] Another study found that patients with melanoma taking statins had better 5-year overall survival compared to those not taking statins. [ 17 ]…”

Section: Introductionmentioning

confidence: 99%

Low-Dose Atorvastatin has Promoting Effect on Melanoma Tumor Growth and Angiogenesis in Mouse Model

Vaseghi,

Ahmadzadeh,

Naji Esfahani

et al. 2023

Advanced Biomedical Research

View full text Add to dashboard Cite

Background: Preclinical evidence indicates that statins possess diverse antineoplastic effects in different types of tumors. However, clinical studies have yielded conflicting results regarding the potential of statins to either increase or decrease the risk of cancer. Our objective was to examine the relationship between the dose of a treatment and its impact on melanoma tumor growth and angiogenesis in an in vivo setting. Materials and Methods: Melanoma cells were injected into C57BL6 mice in four groups. They received 0, 1, 5, and 10 mg/kg of atorvastatin daily. Three others received the mentioned doses one week before the inoculation of melanoma animals. At the end of the third week, the animals were euthanized in a humane manner, and both blood samples and tumor specimens were collected for subsequent analysis. Results: The tumor size was 1.16 ± 0.25 cm3 in a group treated with therapeutic dose of atorvastatin and was significantly larger than that in the control group (0.42 ± 0.08 cm3). However, there were no significant differences between the two other doses and the control group (0.72 ± 0.22, 0.46 ± 0.08 cm3 in atorvastatin-treated groups with 5 and 10 mg/kg). The vascular density of the tumors was significantly increased in the lowest dose of the atorvastatin treatment group, similar to the results of tumor size (P < 0.05). Conclusion: Atorvastatin, at low therapeutic concentrations, has been observed to stimulate tumor growth and exhibit pro-angiogenic effects. Therefore, it is advised to exercise caution and recommend clinically relevant doses of statins to patients with cancer.

show abstract

Unraveling lipid metabolism reprogramming for overcoming drug resistance in melanoma

Wang,

Yan,

Liu

et al. 2024

Biochemical Pharmacology

View full text Add to dashboard Cite

Statin use is associated with improved overall survival in patients with melanoma

Cited by 7 publications

References 7 publications

Association between Statin Use and Survival in Cancer Patients with Brain Metastasis: Retrospective Analysis from the Chinese Population

Association between Statin Use and Survival in Cancer Patients with Brain Metastasis: Retrospective Analysis from the Chinese Population

Low-Dose Atorvastatin has Promoting Effect on Melanoma Tumor Growth and Angiogenesis in Mouse Model

Unraveling lipid metabolism reprogramming for overcoming drug resistance in melanoma

Contact Info

Product

Resources

About